SCHEMBL2881209

SCHEMBL2881209

CC(C)(C)CCN1CCC(F)(CNC(=O)C2(c3ccc(Cl)cc3)CC(F)C2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 8/20 0.57
CACNA1I Q9P0X4 5/20 0.50
DRD2 P14416 6/20 0.43
OPRM1 P35372 4/20 0.39
ADRA2A P08913 2/20 0.39
DRD4 P21917 2/20 0.39
HRH2 P25021 2/20 0.39
SLC6A4 P31645 2/20 0.39
ADRA1A P35348 2/20 0.39
SCN5A Q14524 2/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
HRH1 P35367 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
OPRL1 P41146 1/20 0.39
TRPA1 O75762 1/20 0.39
MEN1 O00255 1/20 0.38
CES2 O00748 1/20 0.38
SLC22A1 O15245 1/20 0.38
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2881211 1.00 KCNH2 (0.57) KCNH2CACNA1IDRD2OPRM1ADRA2A
SCHEMBL2882393 0.91 KCNH2 (0.60) KCNH2CACNA1IDRD2OPRM1ADRA2A
SCHEMBL2889689 0.91 KCNH2 (0.60) KCNH2CACNA1IDRD2OPRM1OPRL1
SCHEMBL2887276 0.91 KCNH2 (0.62) KCNH2CACNA1IDRD2OPRM1ADRA2A
SCHEMBL2884528 0.90 KCNH2 (0.59) KCNH2CACNA1IDRD2OPRM1DRD4
SCHEMBL2880982 0.82 KCNH2 (0.69) KCNH2CACNA1IOPRM1OPRL1TRPA1
SCHEMBL2887146 0.82 KCNH2 (0.58) KCNH2CACNA1IADRA1AHRH3OPRL1
SCHEMBL2887449 0.82 KCNH2 (0.55) KCNH2CACNA1IDRD2OPRM1ADRA1A
SCHEMBL2889298 0.81 KCNH2 (0.60) KCNH2CACNA1IADRA1AHRH3OPRL1
SCHEMBL2885955 0.81 KCNH2 (0.71) KCNH2CACNA1IOPRM1OPRL1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501773-B2 4-fluoro-piperidine T-type calcium channel antagonists MERCK SHARP & DOHME CORP. (US) 2013-08-06 US claimed
EP-1901746-B1 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK SHARP & DOHME (US) 2013-02-20 EP claimed
US-20100216841-A1 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists MERCK SHARP & DOHME LLC 2010-08-26 US claimed
EP-1901746-A2 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS Merck & Co., Inc. (US) 2008-03-26 EP claimed
WO-2007002884-A2 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK & CO., INC. (US) 2007-01-04 WO claimed
US-8501773-B2 4-fluoro-piperidine T-type calcium channel antagonists MERCK SHARP & DOHME CORP. (US) 2013-08-06 US disclosed
EP-1901746-B1 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK SHARP & DOHME (US) 2013-02-20 EP disclosed
US-20100216841-A1 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists MERCK SHARP & DOHME LLC 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216841-A1 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists CACNA1G, CACNA1I, CACNA1H KCNH2 38/4885CACNA1I 2/4885DRD2 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.